Phenomix Sciences

Phenomix Sciences is a precision medicine biotechnology company dedicated to advancing obesity treatment through genetic phenotyping and personalized medicine. The company aims to conquer obesity globally by enhancing the understanding of treatment options tailored to individual needs.

Phenomix Sciences specializes in obesity phenotyping, which involves analyzing the unique genetics, microbiome, and metabolism of individuals. This approach allows healthcare providers to customize treatments based on the specific type of obesity a person has. Their primary product, the MyPhenome® Test, utilizes DNA analysis to predict individual responses to weight loss interventions, helping to match patients with the most effective treatments, including GLP-1 medications and bariatric procedures.

The company is privately held and led by a team of experienced professionals, including CEO Mark Bengall and COO Liv Williamsen.